Add To Watchlist
Share URL
About The Company
CEO
Dr. Giovanni Caforio M.D.
Market Cap
99.65 Billion USD
Sector
Healthcare
Website
https://www.bms.comLast Update
2/22/2024, 12:00:00 PM
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
Read More
Overview
Value
69
Growth
55
Health
53
Management
56
Analyst Opinion
97
Total
60
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
- Has a margin-of-safety above fair value
- Liked by analysts
- Has strong dividend growth
- Very safe dividend
Risk Factors
- There is a history of diluting shareholders
- Disliked by Twitter users
Market Peers
BMY
Key Figures
PE Ratio (TTM)
13.57
Margin Of Safety (DCF)
122.89%
Revenue Growth (5 Year Average)
12.13%
Ratings Consensus
Strong Buy
Share Buybacks
-5.53%
Dividend Yeild (TTM)
4.46%
Valuation
Value Score
69
- ✔ Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
- ✔ Free-cashflow-yeild of 11.88% is better than the market average (4.7%)
- ✔ Margin-of-safety of 122.89% is better than the market average (17.95%)
- ✔ Estimated intrinsic-value of 117.35 USD is higher than current price ( 49.16 USD)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 77.6 USD ✔
Current Price: 52.7 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
13.57x
Free Cashflow Yeild
11.88%
PE/Earnings Growth
N/A
Price/Book
3.61x
Growth
Growth Score
55
- ✔ 5 Year Average Revenue growth of 12.13% is higher than the market average (10.97%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 18.32% is higher than the market average (12.35%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of 8.63% is lower than the market average (14.48%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
12.13%
Earnings Growth
8.63%
Cashflow Growth
18.32%
Health
Health Score
53
Altman Z Score
2.30
Piostroski Score
7.00
Debt/Equity
1.27x
Current Assets/Liabilities
1.25x
Free Cashflow/Total Debt
0.30x
Debt/Capital
1.44x
Dividend
Secure Dividend Score
74
- ✔ Dividend yeild of 4.46% is more than the market average (1.85%)
- ✔ Very safe
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Long term dividend payout ratio of 79.64% is high and may limit growth
- ✘ Payout ratio (TTM) of 59.12% is higher than the average (40%)
- ✘ Dividend growth has been slowing recently
Dividend Yeild
4.46%
Dividend Growth
5.41%
Payout Ratio (Earnings)
59.12%
Payout Ratio (Cashflow)
37.50%
Management
Management Score
56
- ✔ Has returned higher dividends when earnings have risen
- ✔ Return-on-equity of 19.34% is higher than the market average (15%)
- ✔ Return-on-capital-employed of 23.69% is higher than the market average (10%)
- ✘ Has issued new shares whilst share price is low
- ✘ Has a history of diluting shareholders to finance activity
Average Buybacks/Dilution
-5.53%
Recent Buybacks/Dilution
-6.08%
5 Year Price Volitility
14.10%
Return On Assets
6.20%
Return On Capital Employed
23.69%
Return On Equity
19.34%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
97
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Bristol-Myers Squibb Company
Currency
USD
Beta
0.415642
Vol Avg
8118334
Ceo
Dr. Giovanni Caforio M.D.
Cik
0000014272
Cusip
110122108
Exchange
New York Stock Exchange
Full Time Employees
34300
Industry
Drug Manufacturers—General
Sector
Healthcare
Ipo Date
1972-06-01
Address
430 East 29th Street
City
New York
State
NY
Country
US
Zip
10016
Phone
212 546 4000
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
28
Twitter Sentiment
0.00
Stocktwits Sentiment
56.00